Found: 12
Select item for more details and to access through your institution.
BAR502/fibrate conjugates: synthesis, biological evaluation and metabolic profile.
- Published in:
- Frontiers in Chemistry, 2024, p. 1, doi. 10.3389/fchem.2024.1425867
- By:
- Publication type:
- Article
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 21, p. 3482, doi. 10.3390/cells11213482
- By:
- Publication type:
- Article
Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation.
- Published in:
- Nutrients, 2020, v. 12, n. 7, p. 1945, doi. 10.3390/nu12071945
- By:
- Publication type:
- Article
The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions.
- Published in:
- Nutrients, 2019, v. 11, n. 8, p. 1820, doi. 10.3390/nu11081820
- By:
- Publication type:
- Article
Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.
- Published in:
- Nutrients, 2019, v. 11, n. 5, p. 1, doi. 10.3390/nu11051132
- By:
- Publication type:
- Article
Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling.
- Published in:
- FASEB Journal, 2022, v. 36, n. 1, p. 1, doi. 10.1096/fj.202101397R
- By:
- Publication type:
- Article
The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy.
- Published in:
- FASEB Journal, 2021, v. 35, n. 1, p. 1, doi. 10.1096/fj.202001386R
- By:
- Publication type:
- Article
Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists.
- Published in:
- Molecules, 2023, v. 28, n. 6, p. 2840, doi. 10.3390/molecules28062840
- By:
- Publication type:
- Article
Discovery of a Potent and Orally Active Dual GPBAR1/CysLT<sub>1</sub>R Modulator for the Treatment of Metabolic Fatty Liver Disease.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.858137
- By:
- Publication type:
- Article
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-28647-4
- By:
- Publication type:
- Article
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.939969
- By:
- Publication type:
- Article
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
- Published in:
- Journal of the American Heart Association, 2023, v. 12, n. 23, p. 1, doi. 10.1161/JAHA.123.031241
- By:
- Publication type:
- Article